Application of a New "Pharmvigill©" App for the Analysis of Dermatological Adverse Drug Reaction in a Tertiary Care Hospital

被引:1
作者
Chawla, Shalini [1 ]
Tiwari, Ankur [2 ]
Syed, Shariq Naeem [3 ]
机构
[1] Maulana Azad Med Coll, Dept Pharmacol, New Delhi, India
[2] Maulana Azad Med Coll, New Delhi, India
[3] Aligarh Muslim Univ, Dept Pharmacol, Jawaharlal Nehru Med Coll, Aligarh 202002, Uttar Pradesh, India
关键词
Adverse drug reactions; Pharmvigill (c) app; skin; SEVERITY;
D O I
10.4103/jpp.JPP_105_18
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: To assess the patterns of dermatological adverse drug reactions (ADRs) and drugs responsible to formulate a strategy for prevention and treatment using a new app. Materials and Methods: In the present study, 870 patients in dermatology outpatient department were screened, out of which sixty cutaneous ADRs were included in the study. The ADRs were categorized and assessed by Causality Assessment Scale and Preventability Scale using an innovative mobile software application named "Pharmvigill (c)-ADR analyzer App." Results: It was observed that rashes and acneiform eruption (25% and 16.7%, respectively) were the most common cutaneous ADRs. Nonsteroidal anti-inflammatory drugs (25%) were the most common group of drugs causing cutaneous ADRs followed by antimicrobial drugs (23.3%) and steroids (20%). Similarly, betamethasone, paracetamol, and phenytoin were the most common drugs causing ADRs. In the causality assessment, almost 81% fell into the category of "probable," whereas 58.8% of the ADRs were "probably preventable" and almost 40% were "not preventable." There was no statistically significant difference (P > 0.05) between scores in manual assessment and software-based assessment. Conclusion: Cutaneous ADRs are caused by some of the very commonly prescribed medicines. A high degree of suspicion is required to identify the "preventable" type of ADR. The ADR analysis app "Pharmvigill" is accurate and can decrease the analysis time of the ADRs in a dynamic clinical scenario.
引用
收藏
页码:69 / 74
页数:6
相关论文
共 14 条
[1]  
Bigby M, 2001, ARCH DERMATOL, V137, P765
[2]   Epidemiology of Adverse Drug Reactions in Europe: A Review of Recent Observational Studies [J].
Bouvy, Jacoline C. ;
De Bruin, Marie L. ;
Koopmanschap, Marc A. .
DRUG SAFETY, 2015, 38 (05) :437-453
[3]  
Campos-Fernández MDM, 2005, REV INVEST CLIN, V57, P770
[4]   Percentage of Patients with Preventable Adverse Drug Reactions and Preventability of Adverse Drug Reactions - A Meta-Analysis [J].
Hakkarainen, Katja M. ;
Hedna, Khadidja ;
Petzold, Max ;
Hagg, Staffan .
PLOS ONE, 2012, 7 (03)
[5]   PREVENTABILITY AND SEVERITY ASSESSMENT IN REPORTING ADVERSE DRUG-REACTIONS [J].
HARTWIG, SC ;
SIEGEL, J ;
SCHNEIDER, PJ .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1992, 49 (09) :2229-2232
[6]  
KRAMER MS, 1981, BRIT J CLIN PHARMACO, V11, pS105
[7]   Incidence of adverse drug reactions in hospitalized patients - A meta-analysis of prospective studies [J].
Lazarou, J ;
Pomeranz, BH ;
Corey, PN .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (15) :1200-1205
[8]  
Nandha Ruchika, 2011, Int J Appl Basic Med Res, V1, P50, DOI 10.4103/2229-516X.81982
[9]   A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS [J].
NARANJO, CA ;
BUSTO, U ;
SELLERS, EM ;
SANDOR, P ;
RUIZ, I ;
ROBERTS, EA ;
JANECEK, E ;
DOMECQ, C ;
GREENBLATT, DJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) :239-245
[10]  
Patel Tejas K, 2014, Indian Dermatol Online J, V5, pS76, DOI 10.4103/2229-5178.146165